IN THE CLAIMS:

Amend the claims as follows.

Claim 1-61. (Canceled)

62. (New) A compound of the formula:



(1)

wherein:

J is a linking functional group and is independently:

-C(=O)- or -O-C(=O)- or -C(=O)-O-;

Cy is a cyclyl group and is independently:

C_{3-20}carbocyclyl, C_{3-20}heterocyclyl, or C_{5-20}aryl;

and is optionally substituted;

Q^1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted;

Q^2 is an acid leader group, and is independently:

C_{1-8}alkylene;

and is optionally substituted;

or:

Q^2 is an acid leader group, and is independently:

C_{5-20}arylene;

C_{5-20}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-20}arylene; or,

C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

63. (New) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O-.

64. (New) A compound according to claim 62, wherein J is -O-C(=O)-.

65. (New) A compound according to claim 62, wherein J is -C(=O)-O-.

66. (New) A compound according to claim 62, wherein J is -C(=O)-.

67. (New) A compound according to claim 62, wherein Q^1 is independently a group of the formula:



wherein:

the ring independently has from 4 to 7 ring atoms;

Z is independently $-CH_2-$, $-N(R^N)-$ or -O-;

R^N, if present, is independently -H, C_{1-7}alkyl, C_{5-20}aryl-C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl; and

Q^1 is optionally further substituted.

68. (New) A compound according to claim 67, wherein Q^1 is independently a group of the formula:



wherein y is independently 1, 2, 3, or 4.

69. (New) A compound according to claim 68, wherein Q^1 is independently selected from:



70. (New) A compound according to claim 69, wherein Q^1 is independently:



71. (New) A compound according to claim 69, wherein Q^1 is independently:



72. (New) A compound according to claim 69, wherein Q^1 is independently:



73. (New) A compound according to claim 67, wherein R^N, if present, is independently selected from: -H, -Me, -Et, -Ph, and -CH_2-Ph.

74. (New) A compound according to claim 67, wherein R^N, if present, is independently -H.

75. (New) A compound according to claim 62, wherein substituents on Q^1, if present, are independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, -NH_2, -NMe_2, -NEt_2, morpholino, -$CONH_2$, -$CONMe_2$, -NHCOMe, and =O;

and wherein, if a substituent is on an arylene group , it may additionally be selected from: -Me, -Et, -iPr, -tBu, -CF_3.

76. (New) A compound according to claim 62, wherein Cy is independently C_{3-20}carbocyclyl; and is optionally substituted.

77. (New) A compound according to claim 62, wherein Cy is independently C_{3-20}heterocyclyl; and is optionally substituted.

78. (New) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl; and is optionally substituted.

79. (New) A compound according to claim 62, wherein Cy is independently C_{5-20}carboaryl or C_{5-20}heteroaryl; and is optionally substituted.

80. (New) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl derived from one of the following:

benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

81. (New) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl derived from benzene and is optionally substituted.

82. (New) A compound according to claim 62, wherein Cy is independently an optionally substituted phenyl group of the formula:



wherein n is independently an integer from 0 to 5, and

each R^A is independently a substituent.

83. (New) A compound according to claim 82, wherein n is 0.

84. (New) A compound according to claim 82, wherein n is 1, and the R^A group is in the 4'-position.

85. (New) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 2'-position.

86. (New) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 3'-position.

87. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) ester;

(2) amido;

(3) acyl;

(4) halo;

(5) hydroxy;

(6) ether;

(7) C_{1-7}alkyl; substituted C_{1-7}alkyl;

(8) C_{5-20}aryl; substituted C_{5-20}aryl;

(9) sulfonyl;

(10) sulfonamido.

88. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) -C(=O)OR^1, wherein R^1 is independently C_{1-7}alkyl as defined in (7);

(2) -C(=O)NR^2R^3, wherein each of R^2 and R^3 is independently -H or C_{1-7}alkyl as defined in (7);

(3) -C(=O)R^4, wherein R^4 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OR^5, wherein R^5 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(7) C_{1-7}alkyl; substituted C_{1-7}alkyl;

halo-C_{1-7}alkyl;

amino-C_{1-7}alkyl;

carboxy-C_{1-7}alkyl;

hydroxy-C_{1-7}alkyl;

C_{1-7}alkoxy-C_{1-7}alkyl;

C_{5-20}aryl-C_{1-7}alkyl;

(8) C_{5-20}aryl; substituted C_{5-20}aryl;

(9) -SO_2R^7, wherein R^7 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(10) -$SO_2NR^8R^9$, wherein each of R^8 and R^9 is independently -H or C_{1-7}alkyl as defined in (7).

89. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe);

$-C(=O)OCH_2CH_2OH$, $-C(=O)OCH_2CH_2OMe$, $-C(=O)OCH_2CH_2OEt$;

(2) $-(C=O)NH_2$, $-(C=O)NMe_2$, $-(C=O)NEt_2$, $-(C=O)N(iPr)_2$, $-(C=O)N(CH_2CH_2OH)_2$;

(3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh;

$-OCF_3$, $-OCH_2CF_3$;

$-OCH_2CH_2OH$, $-OCH_2CH_2OMe$, $-OCH_2CH_2OEt$;

$-OCH_2CH_2NH_2$, $-OCH_2CH_2NMe_2$, $-OCH_2CH_2N(iPr)_2$;

-OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;

(7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe;

$-CF_3$, $-CH_2CF_3$;

$-CH_2CH_2OH$, $-CH_2CH_2OMe$, $-CH_2CH_2OEt$;

$-CH_2CH_2NH_2$, $-CH_2CH_2NMe_2$, $-CH_2CH_2N(iPr)_2$;

$-CH_2$-Ph;

(8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;

(9) $-SO_2Me$, $-SO_2Et$, $-SO_2Ph$;

(10) $-SO_2NH_2$, $-SO_2NMe_2$, $-SO_2NEt_2$.

90. (New) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

-C(=O)OMe, -OMe, -C(=O)Me, -SO_2Me, -SO_2NMe_2, -C(=O)NH_2, -OCF_3, and -CH_2CH_2OH.

91. (New) A compound according to claim 62, wherein the acid leader group, Q^2, is independently:

C_{5-20}arylene;

and is optionally substituted.

92. (New) A compound according to claim 62, wherein Q^2 is independently C_{5-6}arylene; and is optionally substituted.

93. (New) A compound according to claim 62, wherein Q^2 is independently phenylene; and is optionally substituted.

94. (New) A compound according to claim 93, wherein the phenylene linkage is meta or para.

95. (New) A compound according to claim 93, wherein the phenylene linkage is meta.

96. (New) A compound according to claim 93, wherein the phenylene linkage is para.

97. (New) A compound according to claim 91, wherein Q^2 is independently unsubstituted.

98. (New) A compound according to claim 62, wherein the acid leader group, Q^2, is independently:

C_{1-8}alkylene;

and is optionally substituted.

99. (New) A compound according to claim 62, wherein Q^2 is independently:

(a) a saturated C_{1-7}alkylene group; or:

(b) a partially unsaturated C_{2-7}alkylene group; or:

(c) an aliphatic C_{1-7}alkylene group; or:

(d) a linear C_{1-7}alkylene group; or:

(e) a branched C_{2-7}alkylene group; or:

(f) a saturated aliphatic C_{1-7}alkylene group; or:

(g) a saturated linear C_{1-7}alkylene group; or:

(h) a saturated branched C_{2-7}alkylene group; or:

(i) a partially unsaturated aliphatic C_{2-7}alkylene group; or:

(j) a partially unsaturated linear C_{2-7}alkylene group; or:

(k) a partially unsaturated branched C_{2-7}alkylene group;

and is optionally substituted.

100. (New) A compound according to claim 62, wherein Q^2 is independently selected from:

$-(CH_2)_5-$; $-(CH_2)_6-$; $-(CH_2)_7-$; and $-(CH_2)_8-$.

101. (New) A compound according to claim 62, wherein Q^2 is independently:

C_{5-20}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-20}arylene; or,

C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene;

and is optionally substituted.

102. (New) A compound according to claim 62, wherein Q^2 is independently:

C_{5-6}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-6}arylene; or,

C_{1-7}alkylene-C_{5-6}arylene-C_{1-7}alkylene;

and is optionally substituted.

103. (New) A compound according to any claim 62, wherein Q^2 is independently:

phenylene-C_{1-7}alkylene;

C_{1-7}alkylene-phenylene; or,

C_{1-7}alkylene-phenylene-C_{1-7}alkylene;

and is optionally substituted.

104. (New) A compound according to claim 62, wherein Q^2 independently has a backbone of from 5 to 6 atoms.

105. (New) A compound according to claim 62, wherein each of the substituents on Q^2, if present, is independently selected from:

halo, hydroxy, ether, C_{1-7}alkoxy, C_{5-20}aryl, acyl, amino, amido, acylamido, nitro, and oxo; and wherein, if a substituent is on an arylene group, it may additionally be selected from: C_{1-7}alkyl and substituted C_{1-7}alkyl.

106. (New) A compound according to claim 62, wherein each of the substituents on Q^2, if present, is independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, $-NH_2$, $-NMe_2$, $-NEt_2$, morpholino, $-CONH_2$, $-CONMe_2$, -NHCOMe, $-NO_2$, and =O; and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, $-CF_3$.

107. (New) A compound of the formula:



(1)

wherein:

J is independently: -C(=O)-O-;

Q^1 is independently:



Q^2 is phenylene, and is optionally substituted;

Cy is phenyl, and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

108. (New) A compound selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof:

1		PX118478

2		PX118479
3		PX118480
4		PX119101
5		PX118925

6		PX118926
7		PX118959
8		PX118966
9		PX119058

10		PX119059
11		PX119061
12		PX119062
13		PX119064

14		PX119065
15		PX119084
16		PX119100
17		PX119063

18		PX119085
19		PX119086
20		PX119102
21		PX119103

22		
23		
24		

109. (New) A composition comprising a compound according to claim 62 and a pharmaceutically acceptable carrier.

110. (New) A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to claim 62.

111. (New) A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to claim 62.

112. (New) A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to claim 62.

113. (New) A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to claim 62.

114. (New) A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to claim 62.